Download PDF
Aktuelle Urol 2008; 39(1): 41-51
DOI: 10.1055/s-2007-1016432
Übersicht
© Georg Thieme Verlag Stuttgart · New York

Neue Medikamente beim metastasierten Nierenzellkarzinom

New Drugs for Metastatic Kidney CancerC.  Doehn1
  • 1Klinik und Poliklinik für Urologie, Universitätsklinikum Schleswig-Holstein (UK S-H), Campus Lübeck
Further Information

Publication History

Publication Date:
28 January 2008 (online)

Also available at
   Permissions and Reprints
Preview

Zusammenfassung

Die systemische Behandlung des metastasierten Nierenzellkarzinoms hat in den letzten Jahren eine rasante Wandlung erfahren. Hierzu haben Erkenntnisse über histologische Subtypen und damit assoziierte genetische Aberrationen entscheidend beigetragen. Außerdem sind verschiedene Signalwege identifiziert worden, die für eine Tumorprogression bzw. therapeutische Beeinflussbarkeit bedeutsam sind. Bis vor wenigen Jahren stand lediglich eine Immuntherapie unter Verwendung von Zytokinen zur Verfügung. In der vorliegenden Übersichtsarbeit werden neue Medikamente zur Therapie des metastasierten Nierenzellkarzinoms dargestellt. Diese beeinflussen insbesondere die VEGF-, EGFR- und mTOR-Signalwege. Vier Substanzen sind in Phase-III-Studien geprüft worden und für die Therapie des metastasierten Nierenzellkarzinoms zugelassen bzw. werden in Kürze zugelassen. Ferner gibt es eine Vielzahl von Substanzen, die Phase-I und –II-Studien getestet wurden oder werden. Derzeit existieren verschiedene Szenarien, welche die Therapieentscheidung beeinflussen. Hierzu gehören verschiedene Prognosegruppen, der Einsatz in der Erstlinien- bzw. Zeitlinientherapie, der Einsatz verschiedener Kombinationen sowie der Einfluss der histologischen Subtypen.

Abstract

Systemic therapy of metastatic kidney cancer has undergone dramatic changes over the past years. One reason for this is our increasing knowledge of different histological subtypes and associated genetic aberrations. Furthermore, signalling pathways have been identified to be relevant for tumour progression and therapeutic intervention. Until some years ago, systemic therapy for kidney cancer consisted of cytokines. In this review, new drugs for the treatment of metastatic kidney cancer are discussed. These drugs predominantly interact the VEGF, EGFR and mTOR signalling pathways. Four drugs have been studied in phase III trials and were (or will soon be) approved for treatment of metastatic kidney cancer. Additionally, many drugs are currently being tested in phase I and phase II trials. At present, the following scenarios have an impact on therapy decisions: different prognostic groups, first-line and second-line therapy, combination therapies and the impact of different histological subtypes.

Schlüsselwörter

Nierenzellkarzinom - Immuntherapie - Zytokine - Antikörper - Tyrosinkinase - small molecules - VEGF - EGFR - mTOR

Key words

kidney cancer - immunotherapy - cytokines - antibodies - tyrosine kinase - small molecules - VEGF - EGFR - mTOR

Literatur

  • 1 http://www.rki.de (aufgerufen am 20.11.2007)
  • 2 Motzer R J, Bacik J, Murphy B A, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.  J Clin Oncol. 2002;  20 289-296
    Search in Google Scholar
  • 3 Bukowski R M, Negrier S, Elson P. Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group.  Clin Cancer Res. 2004;  10 6310S-6314S
    Search in Google Scholar
  • 4 Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer.  Cochrane Database Syst Rev. 2005;  (1) CD001425
    Search in Google Scholar
  • 5 Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, Douillard J Y, Chevreau C, Lasset C, Blay J Y. Groupe Francais d’Immunotherapie . Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 – from the Groupe Francais d’Immunotherapie.  J Clin Oncol. 2004;  22 2371-2378
    Search in Google Scholar
  • 6 Negrier S, Chabaud S, Escudier B, Ravaud A, Chevreau C, Blay J Y, Delva R, Biota C, Perol D, Menetrier-Caux C. Groupe Francais d’Immunotherapie . Serum level of vascular endothelial growth factor (VEGF) as an independent prognostic factor in metastatic renal cell carcinoma (MRCC).  J Clin Oncol. 2007;  25 (18S) 5044
    Search in Google Scholar
  • 7 Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?.  J Clin Pathol. 2004;  57 773-775
    Search in Google Scholar
  • 8 Cohen D, Lane B, Jin T, Magi-Galluzzi C, Finke J, Rini B I, Bukowski R M, Zhou M. The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation.  Clin Genitourin Cancer. 2007;  5 264-270
    Search in Google Scholar
  • 9 De Mulder P H, Roigas J, Gillessen S, Srinivas S, Pisa P, Vogelzang N, Fountzilas G, Peschel C, Baum C, Escudier B. A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC).  J Clin Oncol. 2006;  24 (18S) 4529
    Search in Google Scholar
  • 10 Motzer R J, Rini B I, Bukowski R M, Curti B D, George D J, Hudes G R, Redman B G, Margolin K A, Merchan J R, Wilding G, Ginsberg M S, Bacik J, Kim S T, Baum C M, Michaelson M D. Sunitinib in patients with metastatic renal cell carcinoma.  JAMA. 2006;  295 2516-2524
    Search in Google Scholar
  • 11 Rosenberg J E, Motzer R J, Michaelson M D, Redman B G, Hudes G R, Bukowski R M, George D J, Kim S T, Baum C M, Wilding G. Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results of two phase II trials and prognostic factor analysis for survival.  J Clin Oncol. 2007;  25 (18S) 5095
    Search in Google Scholar
  • 12 Motzer R J, Hutson T E, Tomczak P, Michaelson M D, Bukowski R M, Rixe O, Oudard S, Negrier S, Szczylik C, Kim S T, Chen I, Bycott P W, Baum C M, Figlin R A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.  N Engl J Med. 2007;  356 115-124
    Search in Google Scholar
  • 13 Szczylik C, Demkow T, Staehler M, Rolland F, Negrier S, Hutson T E, Bukowski R M, Scheuring U J, Burk K, Escudier B. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results.  J Clin Oncol. 2007;  25 (18S) 5025
    Search in Google Scholar
  • 14 Escudier B, Eisen T, Stadler W M, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai A A, Rolland F, Demkow T, Hutson T E, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski R M. TARGET Study Group . Sorafenib in advanced clear-cell renal-cell carcinoma.  N Engl J Med. 2007;  356 125-134
    Search in Google Scholar
  • 15 Bukowski R, Cella D, Gondek K, Escudier B. Sorafenib TARGETs Clinical Trial Group . Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer.  Am J Clin Oncol. 2007;  30 220-227
    Search in Google Scholar
  • 16 Rini B I, Wilding G T, Hudes G, Stadler W M, Kim S, Tarazim J C, Bycott P W, Liau K F, Dutcher J P. Axitinib (AG-013 736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib.  J Clin Oncol. 2007;  25 (18S) 5032
    Search in Google Scholar
  • 17 Rixe O, Bukowski R M, Michaelson M D, Wilding G, Hudes G R, Bolte O, Motzer R J, Bycott P, Liau K F, Freddo J, Trask P C, Kim S, Rini B I. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.  Lancet Oncol. 2007;  8 975-984
    Search in Google Scholar
  • 18 http://www.clinicaltrials.gov (aufgerufen am 20.11.2007)
  • 19 Hutson T E, Davis I D, Machiels J P, de Souza P L, Hong B F, Rottey S, Baker K L, Crofts T, Pandite L, Figlin R. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT).  J Clin Oncol. 2007;  25 (18S) 5031
    Search in Google Scholar
  • 20 Vuky J, Fotoohi M, Isacson C, Dela Cruz J, Otero H, Picozzi V, Aboulafia D, Malpass T, Jacobs A. Phase II trial of imatinib mesylate (formerly known as STI-571) in patients with metastatic renal cell carcinoma (RCC).  Proc Am Soc Clin Oncol. 2003;  22 1672
    Search in Google Scholar
  • 21 Culy C. Bevacizumab: antiangiogenic cancer therapy.  Drugs Today (Barc). 2005;  41 23-36
    Search in Google Scholar
  • 22 Yang J C, Haworth L, Sherry R M, Hwu P, Schwartzentruber D J, Topalian S L, Steinberg S M, Chen H X, Rosenberg S A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.  N Engl J Med. 2003;  349 427-434
    Search in Google Scholar
  • 23 Elaraj D M, White D E, Steinberg S M, Haworth L, Rosenberg S A, Yang J C. A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma.  J Immunother. 2004;  27 259-264
    Search in Google Scholar
  • 24 Escudier B, Koralwski P, Pluzanska A, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Moore N. On behalf of the AVOREN investigators. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma.  J Clin Oncol. 2007;  25 (18S) 3
    Search in Google Scholar
  • 25 Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf I G, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer R J. Global ARCC Trial . Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.  N Engl J Med. 2007;  356 2271-2281
    Search in Google Scholar
  • 26 Amato R J, Misellati A, Khan M, Chiang S. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). Journal of Clinical Oncology, 2006.  ASCO Annual Meeting Proceedings. 2006;  Vol 24 (18S) 4530
    Search in Google Scholar
  • 27 Rowinsky E K, Schwartz G H, Gollob J A, Thompson J A, Vogelzang N J, Figlin R, Bukowski R, Haas N, Lockbaum P, Li Y P, Arends R, Foon K A, Schwab G, Dutcher J. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.  J Clin Oncol. 2004;  22 3003-3015
    Search in Google Scholar
  • 28 Motzer R J, Amato R, Todd M, Hwu W J, Cohen R, Baselga J, Muss H, Cooper M, Yu R, Ginsberg M S, Needle M. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma.  Invest New Drugs. 2003;  21 99-101
    Search in Google Scholar
  • 29 Drucker B, Bacik J, Ginsberg M, Marion S, Russo P, Mazumdar M, Motzer R. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.  Invest New Drugs. 2003;  21 341-345
    Search in Google Scholar
  • 30 Dawson N A, Guo C, Zak R, Dorsey B, Smoot J, Wong J, Hussain A. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma.  Clin Cancer Res. 2004;  10 7812-7819
    Search in Google Scholar
  • 31 Jermann M, Stahel R A, Salzberg M, Cerny T, Joerger M, Gillessen S, Morant R, Egli F, Rhyner K, Bauer J A, Pless M. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.  Cancer Chemother Pharmacol. 2006;  57 533-539
    Search in Google Scholar
  • 32 Hainsworth J D, Sosman J A, Spigel D R, Edwards D L, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.  J Clin Oncol. 2005;  23 7889-7896
    Search in Google Scholar
  • 33 Ravaud A, Gardner J, Hawkins R, Maase H Von der, Zantl N, Harper P, Rolland F, Audhuy B, Machiels J, El-Hariry I. Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC).  J Clin Oncol. 2006;  24 (18S) 4502
    Search in Google Scholar
  • 34 Kondagunta G V, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M, Motzer R J. Phase II trial of bortezomib for patients with advanced renal cell carcinoma.  J Clin Oncol. 2004;  22 3720-3725
    Search in Google Scholar
  • 35 Davis N B, Taber D A, Ansari R H, Ryan C W, George C, Vokes E E, Vogelzang N J, Stadler W M. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.  J Clin Oncol. 2004;  22 115-119
    Search in Google Scholar
  • 36 An J, Rettig M B. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.  Mol Cancer Ther. 2007;  6 61-69
    Search in Google Scholar
  • 37 Amato R J. Thalidomide therapy for renal cell carcinoma.  Crit Rev Oncol Hematol. 2003;  46 (Suppl) S59-65
    Search in Google Scholar
  • 38 Lee C P, Patel P M, Selby P J, Hancock B W, Mak I, Pyle L, James M G, Beirne D A, Steeds S, A’Hern R, Gore M E, Eisen T. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.  J Clin Oncol. 2006;  24 898-903
    Search in Google Scholar
  • 39 Ghobrial I M, Rajkumar S V. Management of thalidomide toxicity.  J Support Oncol. 2003;  1 194-205
    Search in Google Scholar
  • 40 Kumar S, Witzig T E, Rajkumar S V. Thalidomid: current role in the treatment of non-plasma cell malignancies.  J Clin Oncol. 2004;  22 2477-2488
    Search in Google Scholar
  • 41 Olencki T, Malhi S, Mekhail T, Dreicer R, Elson P, Wood L, Bukowski R M. Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma.  Invest New Drugs. 2006;  24 321-326
    Search in Google Scholar
  • 42 Motzer R J, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J, Mazumdar M. Phase II trial of thalidomide for patients with advanced renal cell carcinoma.  J Clin Oncol. 2002;  20 302-306
    Search in Google Scholar
  • 43 Choueiri T K, Dreicer R, Rini B I, Elson P, Garcia J A, Thakkar S G, Baz R C, Mekhail T M, Jinks H A, Bukowski R M. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.  Cancer. 2006;  107 2609-2616
    Search in Google Scholar
  • 44 Harrison M L, Obermueller E, Maisey N R, Hoare S, Edmonds K, Li N F, Chao D, Hall K, Lee C, Timotheadou E, Charles K, Ahern R, King D M, Eisen T, Corringham R, DeWitte M, Balkwill F, Gore M. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose.  J Clin Oncol. 2007;  25 4542-4549
    Search in Google Scholar
  • 45 http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf (aufgerufen am 20.11.2007)
  • 46 Bukowski R, Kabbinavar F F, Figlin R A, Flaherty K, Srinivas S, Vaishampayan U, Drapkin H A, Dutcher J, Ryba S, Xia Q, Scappaticci F A, McDermott D. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.  J Clin Oncol. 2007;  25 4536-4551
    Search in Google Scholar
  • 47 Ryan C W, Goldman B H, Lara Jr P N, Mack P C, Beer T M, Tangen C M, Lemmon D, Pan C X, Drabkin H A, Crawford E D. Southwest Oncology Group . Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.  J Clin Oncol. 2007;  25 3296-3301
    Search in Google Scholar
  • 48 Chan J S, Vuky J, Besaw L A, Beer T M, Ryan C W. A phase II study of mammalian target of rapamycin (mTOR) inhibitor RAD001 plus imatinib mesylate (IM) in patients with previously treated advanced renal carcinoma (RCC).  Kidney Cancer Association Meeting. 2007; 
    Search in Google Scholar
  • 49 Stadler W M, Figlin R A, Ernstoff M S, Curti B, Pendergrass K, Srinivas S, Canfield V, Weissman C, Poulin-Costello M, Bukowski R M. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC).  J Clin Oncol. 2007;  25 (18S) 5036
    Search in Google Scholar

Priv.-Doz. Dr. med. Christian Doehn

Ltd. Oberarzt der Klinik und Poliklinik für Urologie, Universitätsklinikum Schleswig-Holstein (UK S-H), Campus Lübeck

Ratzeburger Allee 160

23538 Lübeck, Deutschland

Phone: 0451–500–6113

Fax: 0451–500–4666

Email: doehn@medinf.mu-luebeck.de

    Editorial Comment zur Übersicht.